WPD Pharmaceuticals Inc.
WBIO
CNSX
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -40.70% | -16.91% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -39.33% | -16.43% | |||
| Operating Income | 39.33% | 16.43% | |||
| Income Before Tax | 350.36% | 88.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 350.36% | 88.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 350.36% | 88.11% | |||
| EBIT | 39.33% | 16.43% | |||
| EBITDA | 40.70% | 16.91% | |||
| EPS Basic | 341.94% | 87.98% | |||
| Normalized Basic EPS | 49.06% | 34.16% | |||
| EPS Diluted | 341.94% | 87.98% | |||
| Normalized Diluted EPS | 49.06% | 34.16% | |||
| Average Basic Shares Outstanding | 1.65% | 0.31% | |||
| Average Diluted Shares Outstanding | 1.65% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
